{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:36:30Z","timestamp":1793702190980,"version":"4.5.1"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of real-time continuous glucose monitoring (CGM) in adults 65 years old and older with type 2 diabetes (T2D) using basal without bolus insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research Design and Methods:<\/jats:title>\n                    <jats:p>\n                      Using data from the MOBILE randomized trial comparing CGM versus blood glucose meter (BGM) monitoring for T2D treated with basal insulin, the treatment effect in participants \u226565 years (range: 65\u201379 years,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200942) was compared with the treatment effect in participants &lt;65 years (range: 33\u201364 years,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009133).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      For participants \u226565 years old, mean change in hemoglobin A1c (HbA1c) was \u22121.08% in the CGM group and \u22120.38% in the BGM group (adjusted mean difference\u2009=\u2009\u22120.65% [95% confidence interval (CI) \u22121.49 to 0.19]). In contrast, the adjusted mean difference in HbA1c between treatment groups was \u22120.35% [95% CI \u22120.77 to 0.07] in the &lt;65 years age group. For time in range 70\u2013180\u2009mg\/dL (TIR), mean adjusted treatment group difference was 19% (95% CI 4 to 35,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.01) in \u226565 years old participants and 12% (95% CI 4 to 19,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.003) in those &lt;65 years old. Comparable treatment group differences favoring the CGM group were observed in both the \u226565 and &lt;65 years age groups for mean glucose and less time &gt;180, 250, and 300\u2009mg\/dL. Hypoglycemia was low in both groups with little difference between treatment groups in both age groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this study of adults with T2D treated with basal insulin without bolus insulin, participants \u226565 years old using CGM had a greater increase in TIR and a reduction in hyperglycemia than those using BGM and the benefit appeared to be at least as great as that observed in younger adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2021.0494","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:59:13Z","timestamp":1640257153000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":78,"title":["Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin"],"prefix":"10.1177","volume":"24","author":[{"given":"Shichun","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bailey","sequence":"additional","affiliation":[{"name":"JAEB Center for Health Research, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5325-7200","authenticated-orcid":false,"given":"Peter","family":"Calhoun","sequence":"additional","affiliation":[{"name":"JAEB Center for Health Research, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8446","authenticated-orcid":false,"given":"Roy W.","family":"Beck","sequence":"additional","affiliation":[{"name":"JAEB Center for Health Research, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6712a2"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3473-8"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2229"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6928"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2855"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817704445"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7444"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14238"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2008.00900.x"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.20982\/tqmp.03.1.p001"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","unstructured":"The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial research group. Diabetes 1995;44:968\u2013983.","DOI":"10.2337\/diab.44.8.968"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2424"},{"key":"e_1_3_5_14_2","unstructured":"Local Coverage Determination: Glucose Monitors [article online] 2021. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33822&ver=31 (accessed November4 2021)."}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2021.0494","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:28Z","timestamp":1777400008000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2021.0494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1089\/dia.2021.0494"],"URL":"https:\/\/doi.org\/10.1089\/dia.2021.0494","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}